BDBM21 CHEMBL24828::N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine::VANDETANIB::ZD-6474::ZD6474::cid_3081361

SMILES COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1

InChI Key InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N

Data  7 KI  96 IC50  914 Kd

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1017 hits for monomerid = 21   Sort by

LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 1.60E+3nMpH: 7.4 T: 2°CAssay Description:An ELISA assay was used to determine the ability of inhibitor to inhibit VEGF-R RTK activity. The compounds were incubated with enzyme 20 min at room...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 40nMT: 2°CAssay Description:An ELISA assay was used to determine the ability of inhibitor to inhibit VEGF-R RTK activity. The compounds were incubated with enzyme 20 min at room...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFibroblast growth factor receptor 1(Human)
Astrazeneca

LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 3.60E+3nMT: 2°CAssay Description:An ELISA assay was used to determine the ability of inhibitor to inhibit VEGF-R RTK activity. The compounds were incubated with enzyme 20 min at room...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 500nMT: 2°CAssay Description:An ELISA assay was used to determine the ability of inhibitor to inhibit VEGF-R RTK activity. The compounds were incubated with enzyme 20 min at room...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:The assay uses purified enzyme interacting with biotinylated peptide substrate. HTRF is based on the proximity of europium cryptate (donor fluorophor...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 100nMAssay Description:The assay uses purified enzyme interacting with biotinylated peptide substrate. HTRF is based on the proximity of europium cryptate (donor fluorophor...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase ABL1 [T315I](Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  78nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetALK tyrosine kinase receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  2.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetAurora kinase C(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.50E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.20E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  320nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEpidermal growth factor receptor [G719C](Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.60nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 3 [1-975](Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase receptor UFO(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  250nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 7(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  50nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 7(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  2.40E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-B receptor 4(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  520nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.20E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetVascular endothelial growth factor receptor 3(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase FRK(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  170nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  260nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  850nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  560nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  830nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.80E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetFibroblast growth factor receptor 1(Human)
Astrazeneca

LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  560nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase Fgr(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  270nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase Fyn(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  360nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase Lck(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  17nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase Lyn(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  110nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetProtein-tyrosine kinase 6(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  160nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetSerine/threonine-protein kinase TNNI3K(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  2.80E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  5.10E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  530nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  67nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  82nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL1 [1-999,Q252H](Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.00E+5nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  94nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase ABL2(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  69nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetTyrosine-protein kinase CSK(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  2.50E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetCasein kinase I isoform epsilon(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  3.00E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Astrazeneca

LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.80nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.70E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 2(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.10E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 4(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.60E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 5(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  240nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-A receptor 8(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  91nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-B receptor 1(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  290nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
TargetEphrin type-B receptor 2(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  440nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails
PCBioAssay
Displayed 1 to 50 (of 1017 total ) | Next | Last >>